# The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

> **NCT04347005** · PHASE1 · COMPLETED · sponsor: **Arthrosi Therapeutics** · enrollment: 64 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Cohort 1: AR882
- **DRUG:** Cohort 2: AR882
- **DRUG:** Cohort 3: AR882
- **DRUG:** Cohort 4: AR882
- **DRUG:** Cohort 5: AR882
- **DRUG:** Cohort 6: AR882 Food Effect
- **DRUG:** Cohort 7: AR882 Solid Oral Formulation
- **DRUG:** Cohort 8: AR882 in combination with allopurinol
- **DRUG:** Cohort 9: AR882 in combination with febuxostat

## Key facts

- **NCT ID:** NCT04347005
- **Lead sponsor:** Arthrosi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-22
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04347005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04347005, "The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04347005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*